Gilead and Arcus see survival boost with gastric cancer combo

14 October 2025

US biotech Arcus Biosciences (NYSE: RCUS) and partner Gilead Sciences (Nasdaq: GILD) have unveiled encouraging survival data for domvanalimab in gastric cancer, with new results presented in a mini oral session at the ESMO 2025 Congress.

The findings keep domvanalimab in contention as one of the last anti-TIGIT antibodies still in late-stage development, after multiple candidates from Roche (ROG: SIX), GSK (LSE: GSK) and others faltered. Unlike most earlier contenders, domvanalimab is designed to be Fc-silent, an approach Arcus believes could deliver a differentiated efficacy and safety profile.

Phase II and Phase III data

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK